157 related articles for article (PubMed ID: 28441737)
1. Commitment of Scaffold Proteins in the Onco-Biology of Human Colorectal Cancer and Liver Metastases after Oxaliplatin-Based Chemotherapy.
Rotoli D; Morales M; Ávila J; Maeso MDC; García MDP; Mobasheri A; Martín-Vasallo P
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28441737
[TBL] [Abstract][Full Text] [Related]
2. IQGAP1, AmotL2, and FKBP51 Scaffoldins in the Glioblastoma Microenvironment.
Rotoli D; Morales M; Maeso MD; Ávila J; Pérez-Rodríguez ND; Mobasheri A; van Noorden CJF; Martín-Vasallo P
J Histochem Cytochem; 2019 Jul; 67(7):481-494. PubMed ID: 30794467
[TBL] [Abstract][Full Text] [Related]
3. FKBP51, AmotL2 and IQGAP1 Involvement in Cilastatin Prevention of Cisplatin-Induced Tubular Nephrotoxicity in Rats.
González-Fernández R; González-Nicolás MÁ; Morales M; Ávila J; Lázaro A; Martín-Vasallo P
Cells; 2022 May; 11(9):. PubMed ID: 35563891
[TBL] [Abstract][Full Text] [Related]
4. Alterations in IQGAP1 expression and localization in colorectal carcinoma and liver metastases following oxaliplatin-based chemotherapy.
Rotoli D; Morales M; Maeso MDC; García MDP; Gutierrez R; Valladares F; Ávila J; Díaz-Flores L; Mobasheri A; Martín-Vasallo P
Oncol Lett; 2017 Sep; 14(3):2621-2628. PubMed ID: 28928806
[TBL] [Abstract][Full Text] [Related]
5. Expression and localization of the immunophilin FKBP51 in colorectal carcinomas and primary metastases, and alterations following oxaliplatin-based chemotherapy.
Rotoli D; Morales M; Del Carmen Maeso M; Del Pino García M; Morales A; Ávila J; Martín-Vasallo P
Oncol Lett; 2016 Aug; 12(2):1315-1322. PubMed ID: 27446431
[TBL] [Abstract][Full Text] [Related]
6. AmotL2, IQGAP1, and FKBP51 Scaffold Proteins in Glioblastoma Stem Cell Niches.
Rotoli D; Díaz-Flores L; Gutiérrez R; Morales M; Ávila J; Martín-Vasallo P
J Histochem Cytochem; 2022 Jan; 70(1):9-16. PubMed ID: 34165350
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases.
Kornmann M; Fakler H; Butzer U; Beger HG; Link KH
Anticancer Res; 2000; 20(5A):3259-64. PubMed ID: 11062751
[TBL] [Abstract][Full Text] [Related]
8. Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study.
Baba H; Baba Y; Uemoto S; Yoshida K; Saiura A; Watanabe M; Maehara Y; Oki E; Ikeda Y; Matsuda H; Yamamoto M; Shimada M; Taketomi A; Unno M; Sugihara K; Ogata Y; Eguchi S; Kitano S; Shirouzu K; Saiki Y; Takamori H; Mori M; Hirata T; Wakabayashi G; Kokudo N
Oncotarget; 2015 Oct; 6(32):34004-13. PubMed ID: 26372896
[TBL] [Abstract][Full Text] [Related]
9. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.
Takahashi M; Hasegawa K; Oba M; Saiura A; Arita J; Sakamoto Y; Shinozaki E; Mizunuma N; Matsuyama Y; Kokudo N
Invest New Drugs; 2016 Aug; 34(4):468-73. PubMed ID: 27155613
[TBL] [Abstract][Full Text] [Related]
11. Hepatic sinusoidal obstruction syndrome reduces the effect of oxaliplatin in colorectal liver metastases.
Robinson SM; White SA
Histopathology; 2012 Dec; 61(6):1247-8. PubMed ID: 23043422
[No Abstract] [Full Text] [Related]
12. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy.
Bismuth H; Adam R
Semin Oncol; 1998 Apr; 25(2 Suppl 5):40-6. PubMed ID: 9609107
[TBL] [Abstract][Full Text] [Related]
13. Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells.
Tanaka S; Hosokawa M; Yonezawa T; Hayashi W; Ueda K; Iwakawa S
Biol Pharm Bull; 2015; 38(3):435-40. PubMed ID: 25757925
[TBL] [Abstract][Full Text] [Related]
14. Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 Sep; 33(9):3941-6. PubMed ID: 24023332
[TBL] [Abstract][Full Text] [Related]
15. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases.
Benoist S; Nordlinger B
Ann Surg Oncol; 2009 Sep; 16(9):2385-90. PubMed ID: 19554377
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
[TBL] [Abstract][Full Text] [Related]
17. The influence of metastatic site on the expression of CEA and cellular localization of β-catenin in colorectal cancer.
Rao US; Hoerster NS; Thirumala S; Rao PS
J Gastroenterol Hepatol; 2013 Mar; 28(3):505-12. PubMed ID: 23216017
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.
Hsu HC; Chou WC; Shen WC; Wu CE; Chen JS; Liau CT; Lin YC; Yang TS
Anticancer Res; 2013 Aug; 33(8):3317-25. PubMed ID: 23898098
[TBL] [Abstract][Full Text] [Related]
19. Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma.
Tural D; Akar E; Öztürk MA; Yıldız Ö; Turna H; Serdengeçti S
J Cancer Res Ther; 2014; 10(3):745-8. PubMed ID: 25313774
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and efficacy of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of Stage IV colorectal cancer.
Nakayama I; Suenaga M; Wakatsuki T; Ichimura T; Ozaka M; Takahari D; Shinozaki E; Chin K; Ueno M; Mizunuma N; Yamaguchi T
Cancer Chemother Pharmacol; 2015 Jul; 76(1):133-9. PubMed ID: 25994854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
